Key statistics
On Friday, MediciNova Inc (MNOV:NMQ) closed at 2.13, -16.47% below its 52-week high of 2.55, set on Nov 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.96 |
---|---|
High | 2.13 |
Low | 1.93 |
Bid | 2.10 |
Offer | 2.13 |
Previous close | 2.00 |
Average volume | 308.76k |
---|---|
Shares outstanding | 49.05m |
Free float | 47.58m |
P/E (TTM) | -- |
Market cap | 98.09m USD |
EPS (TTM) | -0.2099 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
- MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
- MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
- MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
- MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
- MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
More ▼